Drugs / SP-002
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06344052 | Apr 2024 → Sep 2026 expected | basal cell carcinoma | Stamford Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06344052 ↗ |
| Route | Other | “designed for intra-tumoral administration” NCT06344052 ↗ |